Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2021-04-28 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January - 31 March 2021. It contains detailed financial information, including net sales, profit/loss, earnings per share, and cash flow, as well as extensive management commentary on clinical trials, project pipelines, and strategic milestones. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-04-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY 1 - MARCH 31, 2021' and contains detailed financial statements, including net sales, loss after tax, and cash flow data for the first quarter. It also provides comprehensive business updates, pipeline status, and management commentary. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-04-28 English
Annual Report 2020
Annual Report Classification · 100% confidence The document is a comprehensive annual report for BioInvent International for the year 2020. It includes a table of contents, CEO statement, business strategy, clinical highlights, financial summaries (Nettoomsättning, Årets resultat), and detailed financial statements (Koncernens rapport över finansiell ställning, etc.). It is clearly the full annual report, not an announcement or summary. FY 2020
2021-04-08 Swedish
Annual Report 2020
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2020' and contains comprehensive sections typical of a full annual report, including a CEO statement, business model, clinical highlights, financial tables (consolidated income statement, balance sheet, cash flows), accounting principles, and an auditor's report. It is clearly the full annual report rather than an announcement or summary. FY 2020
2021-04-08 English
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a 'Change in the number of shares and votes' for BioInvent International AB as of March 31, 2021. It details the issuance of 16,260,601 new shares resulting from a directed issue approved by the General Meeting. This action directly relates to a change in the company's capital structure via share issuance. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general financing update (CAP), nor is it a dividend notice (DIV) or a transaction in own shares (POS, which usually implies buybacks or treasury stock transactions, whereas this is an issuance to external investors).
2021-03-31 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement dated March 31, 2021, titled "Ändring av antalet aktier och röster i BioInvent International AB" (Change in the number of shares and votes in BioInvent International AB). It explicitly states the new total number of shares and attributes the change to a directed share issue approved previously. This directly relates to changes in the company's capital structure (issuance of new shares). Based on the definitions, this fits best under 'Share Issue/Capital Change' (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). The final sentence confirms it is information the company is obliged to disclose, suggesting a regulatory filing, but the content is specifically about share count change, making SHA the most precise fit.
2021-03-31 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.